Cellular Dynamics, Roche Update Alliance Covering Cardiotoxicity Platform | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that its agreement with Roche to substantiate CDI's platform for assessing the potential toxicity of drug candidates for heart disease has progressed to a standard supply agreement.

The two-year agreement, which took effect in March 2009, to substantiate CDI's iCell Cardiomyocytes as a predictive tool was completed early, and the platform will now be incorporated into Roche's drug development decision-making process, CDI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.